FIGURE

Figure 3

ID

ZDB-FIG-220131-136

Publication

Bu et al., 2021 - Inhibition of mTOR or MAPK ameliorates vmhcl/myh7 cardiomyopathy in zebrafish

Other Figures

All Figure Page

Back to All Figure Page

Figure 3

A screen of compounds targeting 7 known CM pathways identified therapeutic compounds for VEC.

(A and B) Representative images and percentage of vmhcl^e13/e13 mutant fish with the indicated phenotypes after administration of the compounds or DMSO control at 5 dpf. Black stars indicate severe edema, and red stars indicate mild edema. It is anticipated that 25% of vmhcl^e13/+ incross offspring are homozygous vmhcl^e13/e13, which manifest severe pericardial edema (black stars). Administration of 5 different drugs reduced the percentage of vmhcl^e13/e13 mutants with edema to less than 20%; 3 of these drugs reduced the percentage with edema with statistical significance (P < 0.05). n = 84–122; χ² test; scale bar: 500 μm. (C) Percent FS of the vmhcl^e13/e13 mutants after administration of the compounds compared to WT control at 5 dpf. n = 8; data are presented as the mean ± SD; 1-way ANOVA.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Fish:	myh7l^xu093/xu093
Conditions:	chemical treatment by environment: carvedilol chemical treatment by environment: cyclosporin A chemical treatment by environment: PD 0325901 chemical treatment by environment: sirolimus chemical treatment by environment: sildenafil chemical treatment by environment: vorinostat
Observed In:	heart adenylate cyclase-activating adrenergic receptor signaling pathway heart TOR complex heart contraction MAPK cascade pericardium regulation of autophagy
Stage:	Day 5

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ JCI Insight